Citations

Clear

3485 citation(s) found for "Sy, Sarah".

The Disparate Influence of Bullying on Student Wellbeing: Race, Weight, and Place
Atunah-Jay, Sarah J. , Basappa, Susanna , Harden, Kristin, Phelan, Sean M.

Mayo Clinic

Pediatrics | March 1, 2023 | Volume: 146 | Issue: 1_MeetingAbstract | Pages: 578-579

10.1542/peds.146.1ma6.578 Get It

Safety and Tolerability of Concentrated Intraventricular Nicardipine for Poor-Grade Aneurysmal Subarachnoid Hemorrhage–Related Vasospasm
Zahra, Kaneez , Santos, Christan D. , Peacock, Sarah , Jackson, Daniel A., Siegel, Jason , Freeman, William D. , Peacock, Sarah H, Siegel, Jason L, Freeman, William D , Domingo, Ricardo A. , Turnbull, Marion T. , Tawk, Rabih G.

Mayo Clinic

Journal of Personalized Medicine | February 27, 2023 | Volume: 13 | Issue: 3 | Pages: 428

10.3390/jpm13030428 | PMID 36983610 Get It

Objective: To report the preliminary safety, tolerability, and cerebral spinal fluid (CSF) sampling utility of serial injections of concentrated intraventricular nicardipine (IVN) in the treatment of aneurysmal subarachnoid hemorrhage (aSAH). Methods: We report the clinical, radiographic, and laboratory safety and tolerability data of a retrospective case series from a single academic medical center. All patients with aSAH developed vasospasm despite enteral nimodipine and received serial injections of concentrated IVN (2.5 mg/mL). CSF injection safety, tolerability, and utility are defined and reported. Results: A total of 59 doses of concentrated IVN were administered to three patients with poor-grade SAH. In Case 1, a 33-year-old man with modified Fisher scale (mFS) grade 4 and Hunt-Hess scale (HH) score 4 received 26 doses; in Case 2, a 36-year-old woman with mFS grade 4 and HH score 5 received 13 doses; and in Case 3, a 70-year-old woman with mFS grade 3 and HH score 4 received 20 doses. No major safety or tolerability events occurred. Two patients were discharged to a rehabilitation facility, and one died after discharge from the hospital. Conclusions: A concentrated 4 mg IVN dose (2.5 mg/mL) in a 1.6 mL injection appears relatively safe and tolerable and potentially offers a second-line strategy for treating refractory vasospasm in poor-grade SAH without compromising intracranial pressure or cerebral perfusion pressure.
Laryngeal Imaging Study of Glottal Attack/Offset Time in Adductor Spasmodic Dysphonia during Connected Speech
Naghibolhosseini, Maryam , Zacharias, Stephanie R. C. , Zenas, Sarah, Levesque, Farrah, Deliyski, Dimitar D. , Naghibolhosseini, Maryam

Mayo Clinic

Applied Sciences | February 27, 2023 | Volume: 13 | Issue: 5 | Pages: 2979

10.3390/app13052979 | PMID 37034315 Get It

Adductor spasmodic dysphonia (AdSD) disrupts laryngeal muscle control during speech and, therefore, affects the onset and offset of phonation. In this study, the goal is to use laryngeal high-speed videoendoscopy (HSV) to measure the glottal attack time (GAT) and glottal offset time (GOT) during connected speech for normophonic (vocally normal) and AdSD voices. A monochrome HSV system was used to record readings of six CAPE-V sentences and part of the “Rainbow Passage” from the participants. Three raters visually analyzed the HSV data using a playback software to measure the GAT and GOT. The results show that the GAT was greater in the AdSD group than in the normophonic group; however, the clinical significance of the amount of this difference needs to be studied further. More variability was observed in both GATs and GOTs of the disorder group. Additionally, the GAT and GOT time series were found to be nonstationary for the AdSD group while they were stationary for the normophonic voices. This study shows that the GAT and GOT measures can be potentially used as objective markers to characterize AdSD. The findings will potentially help in the development of standardized measures for voice evaluation and the accurate diagnosis of AdSD.
Radiographic predictors of occult intracranial involvement in olfactory neuroblastoma patients
Geltzeiler, Mathew , Ji, Keven Seung Yong , JessMace, C., Almeida, John R. de , Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Cornell, Sarah, Drozdowski, Veronica , Fernandez‐Miranda, Juan C. , Gardner, Paul A. , Hwang, Peter H. , Kalyvas, Aristotelis , Kong, Keonho A., McMillan, Ryan A. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zadeh, Gelareh , Zenonos, Georgios A. , Zwagerman, Nathan T. , Choby, Garret , Almeida, João Paulo , McMillan, Ryan A , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Hwang, Peter H , Geltzeiler, Mathew , Choby, Garret , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van

Mayo Clinic

International Forum of Allergy & Rhinology | February 26, 2023 | Volume: 13 | Issue: 10 | Pages: 1876-1888

10.1002/alr.23145 | PMID 36841933 Get It

AbstractBackgroundTraditional management of olfactory neuroblastoma (ONB) includes margin‐negative resection with removal of cribriform plate, dura, and olfactory bulb, regardless of intracranial disease. This approach may be overtreating certain patients. Our investigation examines risk factors associated with occult intracranial disease to optimize therapeutic outcomes.MethodsThis retrospective, multi‐institutional cohort study examined clinical covariates associated with occult intracranial involvement. Patient demographics, staging, Hyam's grade, and pathologic involvement of dura, olfactory bulb/tract, and brain were collected. Diagnostic imaging was reviewed. Positive and negative predictive value (NPV) were estimated along with effect size estimates. Cox hazard regression examined associations with overall survival (OS) and disease‐free survival (DFS).ResultsA total of 224 subjects with new diagnoses of ONB (2005–2021) were identified. Skull base bone involvement on computed tomography (CT) had the highest NPV for pathologic dura (88.0%), olfactory bulb (88%), and brain involvement (97.3%). Hyam's grade category was significantly associated with dural involvement (φC = 0.26; 95% confidence interval [CI]: 0.16, 0.42). Subjects without radiologic skull base involvement (n = 66) had pathologic positivity of 12.1%. Within this subgroup, Hyam's grade was clinically significant for dural positivity (φ = 0.34; 95% CI: −0.12, 0.71) with 28.6% involvement in high grade tumors. Neither clinical nor pathologic positivity of intracranial structures were associated with significantly different OS or DFS.ConclusionsBoth CT and magnetic resonance imaging (MRI) had reasonably good NPV for involvement of dura and olfactory bulb. Higher Hyam's grade was associated with dural involvement. Patients with low‐grade tumors not involving the skull base may be suitable for avoiding skull base resection; however, further investigation is warranted.
Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
Ragon, Brittany Knick , Shah, Meera , D’Souza, Anita , Estrada‐Merly, Noel, Gowda, Lohith , George, Gemlyn , Lima, Marcos de , Hashmi, Shahrukh K. , Kharfan‐Dabaja, Mohamed A. , Majhail, Navneet S. , Banerjee, Rahul , Saad, Ayman , Hildebrandt, Gerhard , Mian, Hira , Abid, Muhammad Bilal , Lekakis, Lazaros J. , Strouse, Christopher , Aljurf, Mahmoud , Vesole, David H. , Lee, Cindy H. , Pawarode, Attaphol , Miller, Kevin C. , Holmberg, Leona , Afrough, Aimaz , Solh, Melhem , Munshi, Pashna N. , Anderson, Larry D. , Wirk, Baldeep , Qazilbash, Muzaffar H. , Shah, Nina , Kumar, Shaji , Usmani, Saad Z. , Holmberg, Leona , Shah, Mithun V , de Lima, Marcos , Hashmi, Shahrukh K , Patel, Sagar , Nieto, Yago , Badawy, Sherif M , Dholaria, Bhagirathbhai R , Miller, Kevin C , Nishihori, Taiga , Anderson, Larry D , Kaur, Gurbakhash , Kumar, Shaji K , D'Souza, Anita , Saad, Ayman , Majhail, Navneet S , Banerjee, Rahul , Strouse, Christopher S , Mian, Hira , Usmani, Saad , Abid, Muhammad Bilal , Battiwalla, Minoo , Patel, Sagar S. , Murthy, Hemant S. , Nieto, Yago , Badawy, Sherif M. , Al Hadidi, Samer , Dholaria, Bhagirathbhai , Gergis, Usama , Nishihori, Taiga , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | February 24, 2023 | Volume: 7 | Issue: 12 | Pages: 2746-2757

10.1182/bloodadvances.2022009138 | PMID 36827681 Get It

Abstract The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) and subsequent maintenance therapies in eligible newly diagnosed patients. However, clinical trials using auto-HSCT followed by lenalidomide maintenance have shown an increased risk of second primary malignancies (SPM), including second hematological malignancies (SHM). We evaluated the impact of SPM and SHM on progression-free survival (PFS) and OS in patients with MM after auto-HSCT using CIBMTR registry data. Adult patients with MM who underwent first auto-HSCT in the United States with melphalan conditioning regimen from 2011 to 2018 and received maintenance therapy were included (n = 3948). At a median follow-up of 37 months, 175 (4%) patients developed SPM, including 112 (64%) solid, 36 (20%) myeloid, 24 (14%) SHM, not otherwise specified, and 3 (2%) lymphoid malignancies. Multivariate analysis demonstrated that SPM and SHM were associated with an inferior PFS (hazard ratio [HR] 2.62, P < .001 and HR 5.01, P < .001, respectively) and OS (HR 3.85, P < .001 and HR 8.13, P < .001, respectively). In patients who developed SPM and SHM, MM remained the most frequent primary cause of death (42% vs 30% and 53% vs 18%, respectively). We conclude the development of SPM and SHM leads to a poor survival in patients with MM and is an important survivorship challenge. Given the median survival for MM continues to improve, continued vigilance is needed to assess the risks of SPM and SHM with maintenance therapy post–auto-HSCT.
Motor Speech Phenotypes in Children With Epilepsy: Preliminary Findings
Stoeckel, Ruth , Olsen, Emily , Tallman, Sarah, Iuzzini-Seigel, Jenya , Allison, Kristen , Stoeckel, Ruth , Iuzzini-Seigel, Jenya , Allison, Kristen M.

Mayo Clinic

American Journal of Speech-Language Pathology | February 24, 2023 | Volume: 32 | Issue: 4S | Pages: 1912-1922

10.1044/2022_ajslp-22-00176 | PMID 36827527 Get It

Purpose: This exploratory study aimed to characterize motor speech impairments in a small sample of children with epilepsy, both with and without a known seizure etiology. A secondary aim was to evaluate the validity of the Profile for Childhood Apraxia of speech and Dysarthria (ProCAD), a newly developed tool for differential diagnosis of childhood apraxia of speech and dysarthria. Method: Thirteen children with seizure disorders completed a comprehensive speech and language assessment. Three expert speech-language pathologists rated the presence of auditory-perceptual features of motor speech impairment using the ProCAD. Motor speech features, diagnoses, and standardized test scores were compared between children with a known seizure etiology and children with idiopathic epilepsy. Results: Nine of the 13 children exhibited motor speech impairment; dysarthria was the most common diagnosis. Most children (11/13) exhibited language impairment. Group comparisons showed that children with a known seizure etiology had more atypical motor speech features and lower language scores than children with idiopathic seizures. Conclusion: These preliminary findings suggest a high rate of motor speech impairment among children with epilepsy.
How gender disparities affect otolaryngology specialty selection: an international cross-sectional survey
Nuss, Sarah , Denton, Alexa, Aragão, João, Sprow, Holly N. , Daudu, Davina , Kondamuri, Neil S. , Hampton, T., O’Byrne, Thomas J., Wiedermann, Joshua P.

Mayo Clinic

International Journal of Surgery: Global Health | February 23, 2023 | Volume: 6 | Issue: 2 | Pages: e116-e116

10.1097/gh9.0000000000000116 Get It

Introduction: Most studies evaluating gender disparities in surgical specialties as a career choice are limited to high-income countries and have largely evaluated surgical subspecialties in aggregate. Objective: This study aimed to describe gender-based differences in otolaryngology specialty selection amongst medical students, trainees, and attendings/consultants across both low- and middle-income (LMICs) and high-income countries. Materials and methods: An online cross-sectional survey with 2 arms was administered. The first arm asked medical students about gender-related factors that impact interest in otolaryngology. The second arm asked otolaryngology residents and attendings about gender-related factors that impacted otolaryngology specialty selection and career satisfaction. Descriptive statistics were used to summarize patient demographics and survey responses. Responses were compared by gender using χ2 and Fisher Exact tests. Subgroup analyses between gender and country income status were also conducted. Results: There were 67 medical student respondents (45% male, 54% female, 1.5% nonbinary) and 38 attending/consultant or resident respondents (47% male, 53% female, 0% nonbinary). Thirty-six (36%) of medical students were from LMICs, while 45% of attending/residents were from LMICs. Overall, the results demonstrated gender discrimination and gender-based barriers against female medical students considering otolaryngology and otolaryngologists worldwide that may not be recognized by their male colleagues. Conclusion: The results of these surveys highlight the need for continued education and anti-discrimination policy and advocacy in otolaryngology globally. This information can be leveraged to inform regionally specific research on gender disparities in the otolaryngology workforce and provide a foundation for initiatives to address gender disparities in otolaryngology programs.
Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Guen, Yann Le , Raulin, Ana‐Caroline , Belloy, Michaël E. , Eger, Sarah J. , Kennedy, Gabriel , Kuchenbecker, Lindsey A. , O’Leary, Justin , Panizzon, Matthew S. , Hauger, Richard L. , Gaziano, J. Michael , Bu, Guojun , Thornton, Timothy A. , He, Zihuai , Greicius, Michael D. , Kuchenbecker, Lindsey, O'Leary, Justin P, Bu, Guojun , Raulin, Ana-Caroline , Le Guen, Yann , Belloy, Michael E , Logue, Mark W. , Sherva, Richard , Chen, Shen‐Hsing Annabel , Zhang, Rui , Merritt, Victoria C. , Hauger, Richard L. , Farrer, Lindsay A. , Napolioni, Valerio

Mayo Clinic

JAMA | February 21, 2023 | Volume: 329 | Issue: 7 | Pages: 551

10.1001/jama.2023.0268 | PMID 36809323 Get It

Importance Numerous studies have established the association of the common APOE ε2 and APOE ε4 alleles with Alzheimer disease (AD) risk across ancestries. Studies of the interaction of these alleles with other amino acid changes on APOE in non-European ancestries are lacking and may improve ancestry-specific risk prediction. Objective To determine whether APOE amino acid changes specific to individuals of African ancestry modulate AD risk. Design, Setting, and Participants Case-control study including 31 929 participants and using a sequenced discovery sample (Alzheimer Disease Sequencing Project; stage 1) followed by 2 microarray imputed data sets derived from the Alzheimer Disease Genetic Consortium (stage 2, internal replication) and the Million Veteran Program (stage 3, external validation). This study combined case-control, family-based, population-based, and longitudinal AD cohorts, which recruited participants (1991-2022) in primarily US-based studies with 1 US/Nigerian study. Across all stages, individuals included in this study were of African ancestry. Exposures Two APOE missense variants (R145C and R150H) were assessed, stratified by APOE genotype. Main Outcomes and Measures The primary outcome was AD case-control status, and secondary outcomes included age at AD onset. Results Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male). In stage 2, across multiple cohorts, 1201 cases (median age, 75 [IQR, 69-81] years; 30.8% male) and 2744 controls (median age, 80 [IQR, 75-84] years; 31.4% male) were included. In stage 3, 733 cases (median age, 79.4 [IQR, 73.8-86.5] years; 97.0% male) and 19 406 controls (median age, 71.9 [IQR, 68.4-75.8] years; 94.5% male) were included. In ε3/ε4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10 −6 ) and was associated with a reported younger age at AD onset (β, −5.87 years; 95% CI, −8.35 to −3.4 years; P = 3.4 × 10 −6 ). Association with increased AD risk was replicated in stage 2 (R145C was present in 23 individuals with AD [4.7%] and 21 controls [2.7%]; OR, 2.20; 95% CI, 1.04-4.65; P = .04) and was concordant in stage 3 (R145C was present in 11 individuals with AD [3.8%] and 149 controls [2.7%]; OR, 1.90; 95% CI, 0.99-3.64; P = .051). Association with earlier AD onset was replicated in stage 2 (β, −5.23 years; 95% CI, −9.58 to −0.87 years; P = .02) and stage 3 (β, −10.15 years; 95% CI, −15.66 to −4.64 years; P = 4.0 × 10 −4 ). No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H. Conclusions and Relevance In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype. With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.
Preinjury Social Determinants of Health Disparities Predict Postinjury Psychosocial Conditions in Adult Traumatic Brachial Plexus Injuries
Maasarani, Samantha , DeLeonibus, Anthony , Wee, Corinne, Leavitt, Tripp , Lee, Christina D., Khalid, Syed , Layon, Sarah A. , Noland, Shelley S. , Gharb, Bahar Bassiri , Rampazzo, Antonio

Mayo Clinic

Neurosurgery | February 20, 2023 | Volume: 93 | Issue: 1 | Pages: 215-223

10.1227/neu.0000000000002406 | PMID 36807297 Get It

BACKGROUND: Adult traumatic brachial plexus injuries (TBPIs) are life-altering events that can have detrimental effects on a patient's quality of life. OBJECTIVE: To examine how social determinants of health (SDOH) disparities influence the risk of developing new psychosocial conditions after TBPIs in previously psychiatric-naïve patients. METHODS: Between January 2010 and June 2019, a retrospective analysis was performed using PearlDiver's Mariner, an all-payer claims database, to create 3 cohorts: TBPI disparity cohort: patients with TBPI and presence of at least 1 SDOH disparity before injury, TBPI without disparity cohort: patients with TBPI and the absence of any SDOH disparity, and control cohort: patients without TBPIs. RESULTS: The matched population analyzed in this study consisted of 1176 patients who were equally represented in the TBPI disparity cohort (n = 392, 33.33%), TBPI without disparity cohort (n = 392, 33.33%), and control cohort (n = 392, 33.33%). A total of 301 patients developed any psychosocial condition with 4 years of their injury. Patients in the TBPI disparity cohort had significantly higher rates of developing any psychosocial condition (31.12%, P < .0005), depression (22.70%, P = .0032), anxiety (18.62%, P = .0203), drug abuse (7.91%, P = .0060), and alcohol abuse (4.85%, P = .03499) when compared with the other cohorts. Furthermore, the disparity cohort carried a significantly increased risk of developing any psychosocial condition (hazard ratio 1.42, 95% CI 1.09-1.86). The rates of suicide attempt, post-traumatic stress disorder, and divorce did not significantly differ between groups. CONCLUSION: TBPI patients with SDOH disparities are at increased risk of developing new-onset psychosocial conditions, such as depression, anxiety, drug abuse, and alcohol abuse. Level of Evidence: Prognostic Level III.
Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer Network
Booth, Jennifer P , Kelley, Lindsey R., Capozzi, Donna, Prescott, Hillary, Soefje, Scott A. , Pace, Makala B. , Barbour, Sally, Tizon, Ricky F, DeVincenzo, Sarah, Neidecker, Marjorie V. , Soefje, Scott A , Kennerly-Shah, Julie M , Carnes, Cynthia A.

Mayo Clinic

Journal of Oncology Pharmacy Practice | February 20, 2023 | Volume: 29 | Issue: 8 | Pages: 1907-1914

10.1177/10781552231157660 | PMID 36803319 Get It

Introduction Prioritization and acuity tools have been leveraged to facilitate targeted and efficient clinical pharmacist interventions. However, there is a lack of established pharmacy-specific acuity factors in the ambulatory hematology/oncology setting. Therefore, National Comprehensive Cancer Network's Pharmacy Directors Forum conducted a survey to establish consensus on acuity factors associated with hematology/oncology patients that are high priority for ambulatory clinical pharmacist review. Methods A three-round electronic Delphi survey was conducted. During the first round, respondents were asked an open-ended question to suggest acuity factors based on their expert opinion. Respondents were then asked in the second round to agree or disagree with the compiled acuity factors, in which those with ≥75% agreement were included in the third round. The final consensus was defined as a mean score ≥3.33 on a modified 4-point Likert scale (4 = strongly agree, 1 = strongly disagree) during the third round. Results A total of 124 hematology/oncology clinical pharmacists completed the first round of the Delphi survey (invitation response rate, 36.7%), of which 103 completed the second round (response rate, 83.1%) and 84 the third round (response rate, 67.7%). A final consensus was achieved for 18 acuity factors. Acuity factors were identified in the following themes: antineoplastic regimen characteristics, drug interactions, organ dysfunction, pharmacogenomics, recent discharge, laboratory parameters, and treatment-related toxicities. Conclusions This Delphi panel of 124 clinical pharmacists achieved consensus on 18 acuity factors that would identify a hematology/oncology patient as a high priority for ambulatory clinical pharmacist review. The research team envisions incorporating these acuity factors into a pharmacy-specific electronic scoring tool.